Post is pinned.Post has attachment
Globalist Watch International

Post has attachment
An old drug for alcoholism finds new life as cancer treatment
Dec. 6, 2017

By age 38, the patient’s breast cancer had spread to her bones, a typically fatal turn of events. She became an alcoholic, and her doctors stopped all cancer treatment, instead giving her a drug to discourage her drinking. She died 10 years later, after an inebriated fall from a window. But an autopsy revealed something unexpected: Her bone tumors had melted away, leaving only a few cancer cells in her marrow.

That 1971 case report, along with numerous lab studies, have suggested that the 6-decade-old drug disulfiram (commercially known as Antabuse), which makes people feel sick from drinking small amounts of alcohol, might also be a cancer fighter. Now, researchers have finally figured out how—by blocking a molecule that is part of a process that gets rid of cellular waste.

“This paper solves a puzzle that has persisted in cancer research for decades,” says cancer biologist Michele Pagano of New York University School of Medicine in New York City, who was not involved in the study.

Starting in the 1970s, scientists found that disulfiram killed cancer cells and slowed tumor growth in animals. It increased survival in women who had breast tumors removed in a small clinical trial published in 1993. But since then, disulfiram hasn’t gotten much attention for treating cancer, partly because scientists disagreed about how it worked.

In the new study, a Danish-Czech-U.S. team first firmed up the drug’s anticancer effects by combing through Denmark’s unique cancer registry—more than 240,000 cases diagnosed between 2000 and 2013, along with data on the medications each patient took. Of the more than 3000 patients taking Antabuse, the cancer death rate was 34% lower for the 1177 who stayed on the drug compared with those who stopped taking it, the researchers report today in Nature. The drug was an equal opportunity anticancer weapon; its benefits held for prostate, breast, and colon cancer, as well as cancer overall.

The researchers also confirmed that disulfiram slows the growth of breast cancer tumors in mice, particularly if combined with a copper supplement, which was already known to enhance its effects. They then showed that when the mice broke down disulfiram, its main metabolite, ditiocarb, forms a complex with copper that blocks the machinery that cells use to dispose of misfolded and unneeded proteins. “Everything is frozen,” says cancer biologist Jiri Bartek of the Danish Cancer Society Research Center in Copenhagen, a co-leader of the study. Partly because of the resulting protein buildup, the cancer cells become stressed and die.

Although some approved cancer drugs and others in development interfere with the same protein cleanup process, known as the ubiquitin-proteasome system, disulfiram targets only a specific molecular complex within this machinery. That could explain why it is so effective, Pagano says. Bartek’s team also solved another puzzle—why normal cells aren’t harmed by disulfiram, even when patients take it for years. For unclear reasons, the copper metabolite is 10 times more abundant in tumor tissue compared with other tissues, the group found.

Despite the compelling 1971 anecdote, disulfiram probably “is not a cure” for most cancer patients, cautions cancer biologist Thomas Helleday of the Karolinska Institute in Stockholm. However, the drug could help extend the lives of patients with metastatic cancer—it’s already shown evidence of doing so when combined with chemotherapy in a small lung cancer trial. Bartek and collaborators are now launching trials to test a disulfiram-copper combo as a treatment for metastatic breast and colon cancers and for glioblastoma, a type of brain cancer.

Finding a new use for an approved drug is appealing because the compound has already passed safety testing. However, “big pharma probably won’t be interested” in developing disulfiram for cancer because there’s no patent protection on the drug, Bartek says. Still, if the pending clinical trials provide convincing evidence, Halleday points out, oncologists could go ahead and prescribe it anyway as an inexpensive treatment.

Post has attachment
Russia’s Su-57 Stealth Fighter Is Doomed to Fail

December 11, 2017 Tom Cooper

Westerns analysts have concluded that Russia’s fifth-generation Sukhoi Su-57 stealth fighter is unlikely to enter operational service before 2027. Postponements, cost-overruns and research and development-related problems mar the project.

This should come as no surprise. The Su-57 program was never really viable.

Back in early 2006, Russian president Vladimir Putin integrated all of Russia’s aviation companies into a single, state-owned holding — the United Aircraft-building Corporation.

Over the time, UAC absorbed more than 20 aviation companies, and re-organized these into four aircraft-manufacturing divisions. One for combat aircraft, one for military transport aircraft, one for civilian aircraft and one for aircraft components.

In the course of the streamlining, most of the state-owned enterprises became joint-stock companies. However, the government owns at least 90 percent of shares.

Despite the resulting centralized and vertical structure, most of enterprises integrated within UAC have retained some level of autonomy. MiG and Sukhoi both have their own board of directors.

However, with few exceptions, these directors have no say. On the contrary, the entire UAC conglomerate is subject to a board of 14 directors, most of them well-known associates of Putin. Few are skilled industrial managers.

Despite bombastic reports in the Russian media, UAC turned out to be a lame duck. The conglomerate proved capable of re-launching production of types designed back in the late 1980s and early 1990s. Otherwise, UAC is incapable of innovation and adaptation.

The main reason is that most of UAC’s directors are hand-picked yes-sayers — people more than happy to discuss planning, strategies and new projects, but lacking the ability to make hard decisions. Unsurprisingly, over the last 10 years UAC has made promises it cannot fulfill,

In the case of the Su-57, UAC’s crucial failure was the early decision to close its Combat Aircraft Division to foreign investors. The first director of the consortium, former deputy minister of defense and later prime minister Sergey Ivanov, insisted back in 2006 that Russia “plans to develop this sector on its own.”

Combined with the dramatic collapse of the Russian economy in the wake of Western economic sanctions following the Russian invasion of Ukraine, the inflexibility of UAC made the Su-57 impossible to realize. No matter how large or populated, a country with GDP comparable to that of Australia cannot afford to play at being a superpower, fight a protracted war in Syria and develop its own stealth fighter.

The last hope for the project was the serious Indian interest in financing the conversion of the Su-57 into a stealth strike fighter in the class of the Su-30MKI. But the management structures Putin imposed undermined that collaboration.

Of course, the Kremlin’s core interest in the Su-57 is scoring big propaganda points by creating a supposed match for Lockheed’s F-22 Raptor. This is something the business-minded Indian air force is not keen to finance.

And that means the Su-57 is going nowhere fast.

Post has attachment
Alan Watt: The media will do your thinking for you
Dec 4, 2017

Alan watt - The media will do your thinking for you >>
Alan Watt Website:

Post has attachment

Post has attachment

Post has attachment
Alan Watt: Programming the Public to Consent (Death Beckons)
Dec 10, 2017

Post has shared content

Post has attachment
A Message from President Trump
Mark Dice
Dec 10, 2017

A message from President Trump about what's going on. Obama or Bush would never admit these truths to the American people. Order my new book, The True Story of Fake News: How Mainstream Media Manipulates Millions, from Amazon here: or download the e-book from Kindle, iBooks, Google Play, or Nook.

Post has shared content
Wait while more posts are being loaded